160 related articles for article (PubMed ID: 10093625)
1. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
Findlay BP; Walker-Dilks C
Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
[TBL] [Abstract][Full Text] [Related]
2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
3. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
4. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
5. Use of vinorelbine in non-small-cell lung cancer. Provincial Lung Disease Site Group.
Goss GD; Logan DM; Newman TE; Evans WK
Cancer Prev Control; 1997; 1(1):28-38. PubMed ID: 9765724
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.
Lopez PG; Stewart DJ; Newman TE; Evans WK
Cancer Prev Control; 1997; 1(1):18-27. PubMed ID: 9765723
[TBL] [Abstract][Full Text] [Related]
7. Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Goss G; Paszat L; Newman TE; Evans WK; Browman G
Cancer Prev Control; 1998 Feb; 2(1):32-9. PubMed ID: 9765764
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
Figueredo A; Germond C; Maroun J; Browman G; Walker-Dilks C; Wong S
Cancer Prev Control; 1997 Dec; 1(5):379-92. PubMed ID: 9765760
[TBL] [Abstract][Full Text] [Related]
9. Surgical management of early stage invasive breast cancer (stage I and II). Provincial Breast Disease Site Group.
Mirsky D; O'Brien SE; McCready DR; Newman TE; Whelan TJ; Levine MN
Cancer Prev Control; 1997; 1(1):10-7. PubMed ID: 9765722
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
11. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
[TBL] [Abstract][Full Text] [Related]
12. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
[TBL] [Abstract][Full Text] [Related]
15. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
[TBL] [Abstract][Full Text] [Related]
16. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin as adjuvant therapy in breast cancer.
Earl H; Iddawela M
Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049
[TBL] [Abstract][Full Text] [Related]
18. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.
Reyno L; Seymour L; Tu D; Dent S; Gelmon K; Walley B; Pluzanska A; Gorbunova V; Garin A; Jassem J; Pienkowski T; Dancey J; Pearce L; MacNeil M; Marlin S; Lebwohl D; Voi M; Pritchard K;
J Clin Oncol; 2004 Jan; 22(2):269-76. PubMed ID: 14722035
[TBL] [Abstract][Full Text] [Related]
19. [Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
Haie-Meder C; Fervers B; Chauvergne J; Fondrinier E; Lhommé C; Guastalla JP; Resbeut M
Bull Cancer; 1999 Oct; 86(10):829-41. PubMed ID: 10572234
[TBL] [Abstract][Full Text] [Related]
20. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]